MedDataX Logo

Temporomandibular Joint and COVID-19

NCT ID: NCT05077189

Last Updated: 2021-10-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

76 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-01

Study Completion Date

2021-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is evidence that CV-19 is associated with joint symptoms, but there are no specific data on the temporomandibular joint (TMJ). It is also known that the systemic health status can impact the immune system. Given all this, this study aimed to investigate the effect of CV-19 and systemic health status, as determined by the American Society of Anesthesiologists (ASA) Physical Status Classification System 12, on TMJ in patients with TMJ complaints using the DC/TMD scale.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study investigates the effect of systemic status, according to American Society of Anesthesiologist (ASA), and COVID-19 on temporomandibular joint (TMJ) disorders using the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale, shown to be valid for assessing TMJ disorders. The study included 76 patients who presented to our clinic with TMJ. Participants were divided into two groups: those with COVID-19 (CV-19, study group) and those without (non-CV-19, control group). These two groups were both further divided into subgroups according to ASA 1 and ASA 2 classification. Power analyses were performed using G\*Power software to determine the required number of patients. Groups were compared using the Symptom Questionnaire, a demographics survey, the Graded Chronic Pain Scale (GCPS), and the Jaw Functional Limitation Scale-20 (JFLS-20) of the DC/TMD. The statistical software program version 1.6.23 was used for statistical analysis. Although joint complaints were more common in ASA 2 patients with CV-19, the groups were not significantly different. The CV-19 ASA 2 group had the highest JFLS-20 score (mean: 1.3±1.5) and the non-CV-19 ASA 1 group had the lowest JFLS-20 score (mean: 0.7±0.8), but the differences were again not significant. Joint complaints were more common and more severe in ASA 2 patients with CV-19, albeit not with statistical significance. More studies are needed to better understand our results.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Temporomandibular Disorder ASA Triad

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Group

Patients with CV-19 and not in the acute period. This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).

Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale

Intervention Type OTHER

4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.

1. Demographics Survey
2. DC/TMD Symptom Questionnaire (SQ)
3. Graded Chronic Pain Scale (GCPS)
4. Jaw Functional Limitation Scale-20 (JFLS-20)

Control Group

Patients without CV-19 This group were then divided into two subgroups each according to ASA (American Society of Anesthesiologist) classification (ASA 1 and ASA 2).

Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale

Intervention Type OTHER

4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.

1. Demographics Survey
2. DC/TMD Symptom Questionnaire (SQ)
3. Graded Chronic Pain Scale (GCPS)
4. Jaw Functional Limitation Scale-20 (JFLS-20)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) scale

4 items of the DC/TMD scale were used in this study to evaluate the TMJ disorders.

1. Demographics Survey
2. DC/TMD Symptom Questionnaire (SQ)
3. Graded Chronic Pain Scale (GCPS)
4. Jaw Functional Limitation Scale-20 (JFLS-20)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* applied to our clinic with TMJ discomfort
* ASA 1 and ASA 2 patients

Exclusion Criteria

* patients with acute CV-19
* Patients who are not in ASA 1 or ASA 2 classification
* Patients under 18 year-old
* Pregnants
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Recep Tayyip Erdogan University Training and Research Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nazife Begüm KARAN

Associated Professor, DDS, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nazife B Karan

Role: PRINCIPAL_INVESTIGATOR

Recep Tayyip Erdogan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nazife Begüm Karan

Rize, Eyalet/Yerleşke, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020/224

Identifier Type: -

Identifier Source: org_study_id